Short-term effects of glipizide (an adenosine triphosphate-sensitive potassium channel inhibitor) on cardiopulmonary hemodynamics and global oxygen transport in healthy and endotoxemic sheep

Shock

Volumn 26, Issue 5, 2006, Pages 516-521

  Lange, Matthias ^a   Szabo, Csaba ^b   Van Aken, Hugo ^a   Williams, William ^b   Traber, Daniel L ^c   Daudel, Fritz ^a   Bröking, Katrin ^a   Salzman, Andrew L ^b   Bone, Hans Georg ^a   Westphal, Martin ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b INOTEK CORPORATION   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Endotoxemia; Glipizide; KATP channel inhibition; Sepsis; Sheep; Systemic inflammatory response syndrome

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ENDOTOXIN; GLIPIZIDE; POTASSIUM CHANNEL BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PH; ARTICLE; BALLOON CATHETER; BOLUS INJECTION; CONTROLLED STUDY; DRUG EFFECT; DRUG INFUSION; ENDOTOXEMIA; FEMALE; FEMORAL ARTERY; HEART FAILURE; HEART HEMODYNAMICS; MEAN ARTERIAL PRESSURE; NONHUMAN; OXYGEN TRANSPORT; PULMONARY ARTERY; SALMONELLA TYPHI;

ADENOSINE TRIPHOSPHATE; ANIMALS; BIOLOGICAL TRANSPORT; ENDOTOXEMIA; FEMALE; GLIPIZIDE; HEART; LUNG; OXYGEN; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; REFERENCE VALUES; RESPIRATORY TRANSPORT; SHEEP, DOMESTIC; SHOCK, SEPTIC;

EID: 33750326342     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000228795.33421.45     Document Type: Article

References (39)

1. Landry DW, Oliver JA: The pathogenesis of vasodilatory shock. N Engl J Med 345:588-595, 2001.
2. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368-1377, 2001.
3. Parrillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, Ognibene FP: Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 113:227-242, 1990.
4. Nelson MT, Huang Y, Brayden JE, Hescheler J, Standen NB: Arterial dilations in response to calcitonin gene-related peptide involve activation of K+ channels. Nature 344:770-773, 1990.
5. Nelson MT, Patlak JB, Worley JF, Standen NB: Calcium channels, potassium channels, and voltage dependence of arterial smooth muscle tone. Am J Physiol 259:C3-C18, 1990.
6. Nelson MT: Ca2+-activated potassium channels and ATP-sensitive potassium channels as modulators of vascular tone. Trends Cardiovasc Med 3:54-60, 1993.
7. Standen NB, Quayle JM, Davies NW, Brayden JE, Huang Y, Nelson MT: Hyperpolarizing vasodilators activate ATP-sensitive K+ channels in arterial smooth muscle. Science 245:177-180, 1989.
8. Nelson MT, Quayle JM: Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 268:C799-C822, 1995.
9. Keung EC, Li Q: Lactate activates ATP-sensitive potassium channels in guinea pig ventricular myocytes. J Clin Invest 88:1772-1777, 1991.
10. Davies NW: Modulation of ATP-sensitive K+ channels in skeletal muscle by intracellular protons. Nature 343:375-377, 1990.
11. Dart C, Standen NB: Activation of ATP-dependent K+ channels by hypoxia in smooth muscle cells isolated from the pig coronary artery. J Physiol 483:29-39, 1995.
12. Daut J, Maier-Rudolph W, von Beckerath N, Mehrke G, Gunther K, Goedel-Meinen L: Hypoxic dilation of coronary arteries is mediated by ATP-sensitive potassium channels. Science 247:1341-1344, 1990.
13. Quayle JM, Nelson MT, Standen NB: ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev 77:1165-1232, 1997.
14. Landry DW, Oliver JA: The ATP-sensitive K+ channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog. J Clin Invest 89:2071-2074, 1992.
15. Beech DJ, Zhang H, Nakao K, Bolton TB: K channel activation by nucleotide diphosphates and its inhibition by glibenclamide in vascular smooth muscle cells. Br J Pharmacol 110:573-582, 1993.
16. Ashcroft SJ, Ashcroft FM: Properties and functions of ATP-sensitive K-channels. Cell Signal 2:197-214, 1990.
17. Gribble FM, Ashcroft FM: Differential sensitivity of beta-cell and extra-pancreatic K(ATP) channels to gliclazide. Diabetologia 42:845-848, 1999.
18. Musser JB, Bentley TB, Griffith S, Sharma P, Karaian JE, Mongan PD: Hemorrhagic shock in swine: nitric oxide and potassium sensitive adenosine triphosphate channel activation. Anesthesiology 101:399-408, 2004.
19. Salsbury JR, Biondo N, Salzman AL, Szabo C, Traber LD, Traber DL: Glibenclamide improves hemodynamics in an ovine model of hemorrhagic shock. Crit Care Med 28((suppl)):A139, 2000.
20. Salzman AL, Vromen A, Denenberg A, Szabo C: K(ATP)-channel inhibition improves hemodynamics and cellular energetics in hemorrhagic shock. Am J Physiol 272:H688-H694, 1997.
21. Vanelli G, Hussain SN, Aguggini G: Glibenclamide, a blocker of ATP-sensitive potassium channels, reverses endotoxin-induced hypotension in pig. Exp Physiol 80:167-170, 1995.
22. Westphal M, Sielenkamper AW, Van Aken H, Stubbe HD, Daudel F, Schepers R, Schulte S, Bone HG: Dopexamine reverses the vasopressin-associated impairment in tissue oxygen supply but decreases systemic blood pressure in ovine endotoxemia. Anesth Analg 99:878-885, 2004.
23. Evgenov OV, Pacher P, Williams W, Evgenov NV, Mabley JG, Cicila J, Siko ZB, Salzman AL, Szabo C: Parenteral administration of glipizide sodium salt, an inhibitor of adenosine triphosphate-sensitive potassium channels, prolongs short-term survival after severe controlled hemorrhage in rats. Crit Care Med 31:2429-2436, 2003.
24. Meyer J, Booke M, Waurick R, Prien T, Van Aken H: Nitric oxide synthase inhibition restores vasopressor effects of norepinephrine in ovine hyperdynamic sepsis. Anesth Analg 83:1009-1013, 1996.
25. Scharte M, Meyer J, Van Aken H, Bone HG: Hemodynamic effects of terlipressin (a synthetic analog of vasopressin) in healthy and endotoxemic sheep. Crit Care Med 29:1756-1760, 2001.
26. Westphal M, Stubbe H, Sielenkamper AW, Borgulya R, Van Aken H, Ball C, Bone HG: Terlipressin dose response in healthy and endotoxemic sheep: impact on cardiopulmonary performance and global oxygen transport. Intensive Care Med 29:301-308, 2003.
27. Westphal M, Stubbe H, Sielenkamper AW, Ball C, Van Aken H, Borgulya R, Bone HG: Effects of titrated arginine vasopressin on hemodynamic variables and oxygen transport in healthy and endotoxemic sheep. Crit Care Med 31:1502-1508, 2003.
28. Taylor BS, Geller DA: Molecular regulation of the human inducible nitric oxide synthase (iNOS) gene. Shock 13:413-424, 2000.
29. Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D'Alessandro D, Oz MC, Oliver JA: Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95:1122-1125, 1997.
30. Maybauer DM, Salsbury JR, Westphal M, Maybauer MO, Salzman AL, Szabo C, Westphal-Varghese BB, Traber LD, Traber DL: The ATP-sensitive potassium-channel inhibitor glibenclamide improves outcome in an ovine model of hemorrhagic shock. Shock 22:387-391, 2004.
31. Traber DL: Animal models: the sheep. Crit Care Med 28:591-592, 2000.
32. Bone HG, Schenarts PJ, Fischer SR, McGuire R, Traber LD, Traber DL: Pyridoxalated hemoglobin polyoxyethylene conjugate reverses hyperdynamic circulation in septic sheep. J Appl Physiol 84:1991-1999, 1998.
33. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in the critically ill patients. N Engl J Med 345:1359-1367, 2001.
34. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Jr: Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 33:119-124, 1999.
35. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA: Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 174:169-174, 2006.
36. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352:837-853, 1998.
37. Cleveland JC Jr, Meldrum DR, Cain BS, Banerjee A, Harken AH: Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation 96:29-32, 1997.
38. Bone HG, Waurick R, Van Aken H, Booke M, Prien T, Meyer J: Comparison of the haemodynamic effects of nitric oxide synthase inhibition and nitric oxide scavenging in endotoxaemic sheep. Intensive Care Med 24:48-54, 1998.
39. Leone M, Albanese J, Delmas A, Chaabane W, Garnier F, Martin C: Terlipressin in catecholamine-resistant septic shock patients. Shock 22:314-319, 2004.